Literature DB >> 1608854

Liver disease associated with diclofenac, naproxen, and piroxicam.

H Jick1, L E Derby, L A García Rodríguez, S S Jick, A D Dean.   

Abstract

Based on information derived from computers used by general practitioners in the United Kingdom, we identified all patients with any recorded diagnosis of a liver disorder within 90 days of a prior prescription for diclofenac, naproxen, or piroxicam, three nonsteroidal antiinflammatory drugs (NSAIDs). The follow-up cohort consisted of 102,644 persons who used one or more of these drugs. A case history was requested from the physician to provide a description of the liver disorder and its relation to NSAID exposure. One case of clinically important liver disease was likely to have been caused by a study drug and another appeared to be caused by use of numerous NSAIDs. In 10 additional patients a causal connection between a study NSAID and the liver disorder seemed unlikely but could not be fully ruled out. We conclude that serious liver disease caused by diclofenac, naproxen, or piroxicam appears to be uncommon.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1608854

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  8 in total

Review 1.  Tolerability of topical NSAIDs in the elderly: do they really convey a safety advantage?

Authors:  J M Evans; T M MacDonald
Journal:  Drugs Aging       Date:  1996-08       Impact factor: 3.923

Review 2.  Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review.

Authors:  Una E Makris; Minna J Kohler; Liana Fraenkel
Journal:  J Rheumatol       Date:  2010-04-01       Impact factor: 4.666

Review 3.  Non-steroidal anti-inflammatory drugs: What is the actual risk of liver damage?

Authors:  Fernando Bessone
Journal:  World J Gastroenterol       Date:  2010-12-07       Impact factor: 5.742

Review 4.  Nonsteroidal anti-inflammatory drug-induced hepatic disorders. Incidence and prevention.

Authors:  A V Manoukian; J L Carson
Journal:  Drug Saf       Date:  1996-07       Impact factor: 5.606

Review 5.  Diclofenac potassium 12.5mg tablets for mild to moderate pain and fever: a review of its pharmacology, clinical efficacy and safety.

Authors:  Nicholas Moore
Journal:  Clin Drug Investig       Date:  2007       Impact factor: 2.859

Review 6.  Toxicity of nonsteroidal anti-inflammatory drugs. An overview of the epidemiological evidence.

Authors:  J L Carson; L R Willett
Journal:  Drugs       Date:  1993       Impact factor: 9.546

Review 7.  Diclofenac/misoprostol. A review of its pharmacology and therapeutic efficacy in painful inflammatory conditions.

Authors:  R Davis; Y E Yarker; K L Goa
Journal:  Drugs Aging       Date:  1995-11       Impact factor: 3.923

8.  The role of non-steroidal anti-inflammatory drugs in acute liver injury.

Authors:  L A García Rodríguez; S Pérez Gutthann; A M Walker; L Lueck
Journal:  BMJ       Date:  1992-10-10
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.